Tuesday, 4 February 2025 at 11.00 – 12.00am CET (corrected from 10.00 – 11.00am CET in an earlier version of this invitation)
In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.
The webcast of the conference call will be available during and after the event.
Coloplast will be represented by:
Kristian Villumsen – President & CEO
Anders Lonning-Skovgaard – Executive Vice President, CFO
Aleksandra Dimovska – Vice President, Investor Relations
Simone Dyrby Helvind – Senior Manager, Investor Relations
Webcast
For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:
Access the webcast here
Dial-in details
To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.
Register for the conference call here
For more information, please contact:
Aleksandra Dimovska – Vice President, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 2458. E-mail: dkadim@coloplast.com
Simone Dyrby Helvind – Senior Manager, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 2981. E-mail: dksdk@coloplast.com
Julie Isabella Sommer Müggler – Coordinator & PA, Investor Relations
Tel.: +45 4911 1800 / direct: +45 4911 3161. E-mail: dkjusm@coloplast.com
Coloplast will be available on individual phone lines after the conference call for further questions.
Attachment
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…